ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research, LLC, a leading preclinical CRO, today announced the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
Osteoarthritis is a debilitating disease that affects an enormous number of people. No treatments other than arthroplasty have been developed to stop its progression, reduce pain, and increase range of motion.
This grant will explore a cell therapy approach for the treatment of osteoarthritis via delivery of human mesenchymal stem cells (MSC) and adipose-derived stem cells (ASC) in the form of three-dimensional hydrogels.
L2P Labs will aim to combine the use of hydrogel, stem cells, and ultrasound therapy to develop a new treatment for osteoarthritis. These approaches have shown promise alone and their combination will pave the way for a new therapy to reduce Osteoarthritisassociated pain and improve mobility.
Dr. Suresh Anaganti, Chief Executive Officer of L2P Research, added “This research will address a huge unmet need for disease modification (compared to mere pain management) in the osteoarthritis field. Importantly, these experiments have been designed to facilitate a rapid proof-of-concept to pave the way for future clinical studies.”
About L2P Research
L2P Research, LLC is a Pennsylvania based Research organization that provides integrated R&D support in all the key areas of Pharmaceutical development. With a large worldwide customer base, L2P provides a complete array of research services as required for Investigational New Drug Applications (IND).